Complix N.V., Research Facilities Zwijnaarde (Ghent)

https://www.complix.com

Complix is a biopharmaceutical company developing a pipeline of novel biotherapeutics, called Alphabodies™, for the treatment of cancer and autoimmune diseases. Alphabodies are a revolutionary class of protein therapeutics that have the potential to address a wide range of disease targets, in particular intracellular targets that are considered undruggable by current drug formats, such as antibodies or small chemicals. Complix´ current R&D efforts are focused on the development of Cell Penetrating Alphabodies (CPABs) that have demonstrated a unique capacity to enter tumor cells and tissues effectively and selectively modulate intracellular protein-to-protein interactions (PPIs), which play a key role in the initiation and progression of cancer. In December 2015 Complix signed a strategic collaboration with MSD, through a subsidiary, to develop novel Alphabody based therapeutics against two intracellular cancer targets. Complix is eligible to receive up to $280 million in upfront and development and regulatory milestones as well as tiered mid-single digit royalties on global sales revenues. Since its founding in 2008 Complix has raised a total of more than €27 million in venture financing. *

	Start	2010-09-09 existent
	Group	Complix (Group)
	Industry	biopharmaceutical
	Industry 2	Alphabody™ therapeutic (Alphabodies™)

	Region	Zwijnaarde
	Country	Belgium
	Street	3 Technologiepark
	City	9052 Zwijnaarde
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2025-03-16

Picture Berlin Partner News New Research Centers BeCat S-IM 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]